Monday, 20 May 2019

You are here

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

A prospective registry of CTD and PSV patients enrolled 2140 patients (1534 with CTD, 606 with PSV) between 1999 and 2015. Cases were matched against 15 sex and age matched controls from the Norwegian National Population Registry. 

After a mean follow-up time of 9 years, 279 patients (13%) died, compared with 9% of 32086 controls (P < 0.001).

Lowest 10 year survival was seen in diffuse cutaneous systemic sclerosis (dcSSc) at 60%; this was followed by  73% in anti-synthetase syndrome (ASS) and 75% in limited cutaneous SSc patients.

In the CTD and primary systemic vasculitis (PSV) patients, the highest standard mortality ratios (SMRs) included:

  • dcSSc SMR = 5.8)
  • ASS SMR = 4.1
  • Takayasu arteritis SMR = 2.5
  • ANCA-associated vasculitis SMR = 1.5)

Overall, the major causes of death were cardiovascular disease (CTD 27%, PSV 28%), neoplasms (CTD 25%, PSV 27%), chronic respiratory disease (CTD 20%, PSV10%) and infections (CTD 9%, PSV 16%).

These data call for strategies to address the excess mortality seen among patients with CTD and PSV. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Risk Score Predicts Thrombosis Recurrence in APS

A combination risk score helped predict recurrent thrombosis -- particularly arterial -- among patients with antiphospholipid syndrome (APS), an international study found.

Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus

A Morbidity and Mortality Weekly Report on a registry of systemic lupus erythematosus (SLE) patients from two Georgia counties (Fulton and Dekalb) shows SLE mortality was 2-3 times higher compared to the general population, especially amongst blacks; notably deaths occurred sooner after diagnosis and at a mean age approximately 13 years younger.

Calcineurin Inhibitors in Anti-Synthetase Dermatomyositis ILD

A pilot treatment study of patients with anti-aminoacyl-tRNA synthetase antibody–positive polymyositis/dermatomyositis-associated interstitial lung disease (anti-ARS-PM/DM-ILD) shows therapy with glucocorticoids and calcineurin inhibitors (CNI) to be highly effective. 

Biomarkers Predict Thrombosis in Lupus

A composite risk score that included three biomarkers predicted thrombotic events among patients with systemic lupus erythematosus (SLE), a cross-sectional study found.

Monocyte Patrolling Contributes to Lupus Glomerulonephritis

Systemic lupus erythematosus (SLE) is an autoimmune disease with a propensity to develop glomerulonephritis (47-70%) or end-stage kidney disease despite therapy.

Hallmarks of the disease are the appearance of immune complexes (IC) containing autoreactive Abs and TLR-activating nucleic acids, whose deposition in kidney glomeruli is suspected to promote tissue injury and glomerulonephritis (GN).